NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?

Key Takeaways Novo Nordisk remains the GLP-1 market leader but faces slower sales and rising competition.NVO cut its 2025 outlook amid weaker Wegovy and Ozempic trends.GPCR readies key obesity-drug studies, with data from its aleniglipron studies expected by year-end.Novo Nordisk (NVO) and Structure Therapeutics (GPCR) have emerged as noteworthy companies in the obesity space.A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsu ...